MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock in the atm...
$1,441K
Proceeds from issuance of
common stock in the 2026...
$143K
Proceeds from issuance of
pre-funded warrants in the...
$99K
Proceeds from exercise of
stock options
$54K
(100.00%↑ Y/Y)
Net cash provided by
financing activities
$1,489K
(2190.77%↑ Y/Y)
Canceled cashflow
$248K
Net increase
(decrease) in cash and cash...
-$9,169K
(-192.85%↓ Y/Y)
Canceled cashflow
$1,489K
Stock-based compensation
expense
$972K
(-75.97%↓ Y/Y)
Prepaid expenses and
other assets
-$719K
(-161.98%↓ Y/Y)
Accrued compensation
$482K
(201.05%↑ Y/Y)
Other current
liabilities
$209K
(382.43%↑ Y/Y)
Maturities of investments
$10,000K
(-79.59%↓ Y/Y)
Payment of deferred
offering costs related to...
$248K
Net cash used in
operating activities
-$6,998K
(61.60%↑ Y/Y)
Net cash provided by
investing activities
-$3,660K
(-124.36%↓ Y/Y)
Canceled cashflow
$2,382K
Canceled cashflow
$10,000K
Net loss
-$8,185K
(52.17%↑ Y/Y)
Purchases of investments
$13,660K
(-59.79%↓ Y/Y)
Accounts payable
-$998K
(17.11%↑ Y/Y)
Accrued liabilities
-$103K
(93.13%↑ Y/Y)
Net accretion of
discount on investments
$94K
(-87.33%↓ Y/Y)
Back
Back
Cash Flow
AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc. (ANTX)
source: myfinsight.com